Mylan launches capecitabine tabs

PITTSBURGH — Mylan announced the launch of capecitabine tablets USP in 150-mg and 500-mg dosage strengths. The drug is the generic version of Xeloda tablets from Genentech and is indicated as monotherapy, adjuvant therapy and combination therapy for certain types of breast, colon and colorectal cancers, according to the company.



"The approval of this product, one of a number of key approvals that had been pending with FDA, adds an important product to our broad and growing oncology franchise," said Heather Bresch, Mylan's CEO. "We look forward to bringing a lower cost generic version of this product to patients."



Capecitabine tablets had sales in the United States of approximately $773.8 million for the 12 months ending June 30, 2014, according to IMS Health data.